Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background: Patients with post-traumatic stress disorder frequently report persistent problems with social interactions, emerging after a traumatic experience. Chronic social defeat stress is a widely used rodent model of stress that produces robust and sustained social avoidance behavior. The avoidance of other rodents can be reversed by 28 days of treatment with selective serotonin reuptake inhibitors, the only pharmaceutical class approved by the U.S. Food and Drug Administration for treating post-traumatic stress disorder. In this study, the sensitivity of social interaction deficits evoked by 10 days of chronic social defeat stress to prospective treatments for post-traumatic stress disorder was examined. Methods: The effects of acute and repeated treatment with a low dose of buprenorphine (0.25 mg/kg/d) on social interaction deficits in male C57BL/6 mice by chronic social defeat stress were studied. Another cohort of mice was used to determine the effects of the selective serotonin reuptake inhibitor fluoxetine (10 mg/kg/d), the NMDA antagonist ketamine (10 mg/kg/d), and the selective kappa opioid receptor antagonist CERC-501 (1 mg/kg/d). Changes in mRNA expression of Oprm1 and Oprk1 were assessed in a separate cohort. Results: Buprenorphine significantly reversed social interaction deficits produced by chronic social defeat stress following 7 days of administration, but not after acute injection. Treatment with fluoxetine for 7 days, but not 24 hours, also reinstated social interaction behavior in mice that were susceptible to chronic social defeat. In contrast, CERC-501 and ketamine failed to reverse social avoidance. Gene expression analysis found: (1) Oprm1 mRNA expression was reduced in the hippocampus and increased in the frontal cortex of susceptible mice and (2) Oprk1 mRNA expression was reduced in the amygdala and increased in the frontal cortex of susceptible mice compared to non-stressed controls and stress-resilient mice. Conclusions: Short-term treatment with buprenorphine and fluoxetine normalized social interaction after chronic social defeat stress. In concert with the changes in opioid receptor expression produced by chronic social defeat stress, we speculate that buprenorphine's efficacy in this model of post-traumatic stress disorder may be associated with the ability of this compound to engage multiple opioid receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129 · cited 5×
“Because fluoxetine had only been tested in CSDS following 28 days of treatment (Berton et al, 2006) and SSRIs are the only class of drugs currently approved by the FDA for PTSD, it would be informative to examine the effects of an SSRI on social deficits in a rapid time frame like that of…”
BackgroundMethodSelf-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 2×
“From our data and others, low doses of ketamine (1–10 mg/kg) can alter mouse behavior on tests related to antidepressant activity, such as the FST, NIH test, and reversed the behavioral deficits induced following chronic mild stress (Autry et al., 2011; Browne and Lucki, 2013).”
BackgroundSustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
Self-citationA standardized protocol for repeated social defeat stress in mice
Golden, S. A., Covington, H. E., Berton, O., & Russo, S. J. (2011) · Nature Protocols · doi:10.1038/nprot.2011.361 · Cited by 1,581 · cited 1×
“CSDS is a wellestablished preclinical model of stress that produces pronounced and persistent deficits in social interaction that are long-lasting and sensitive to chronic administration of antidepressant drugs (Berton et al., 2006; Nikulina et al., 2008; Golden et al., 2011).”
BackgroundSelf-citationThe Epidemiology of Trauma, PTSD, and Other Posttrauma Disorders
Breslau, N. (2009) · Trauma, Violence, & Abuse · doi:10.1177/1524838009334448 · Cited by 810 · cited 1×
“Triggered by exposure to an actual or perceived life-threatening event, serious injury, or sexual violence, PTSD is a debilitating mental health disorder (Goldstein et al., 2016), with a current lifetime prevalence of 3.6% in men and 9.7% in women in the United States (Breslau, 2009).”
BackgroundInfluentialMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 1×
“…symptom severity following ketamine infusion in patients with treatment-resistant depression (Zarate et al., 2006; Aan Het Rot et al., 2010; DiazGranados et al., 2010; Ibrahim et al., 2011; Murrough et al., 2013; Ionescu et al., 2016) and possibly in patients with chronic PTSD (Feder et al., 2014).”
BackgroundInfluentialSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564 · cited 1×
“…in symptom severity following ketamine infusion in patients with treatment-resistant depression (Zarate et al., 2006; Aan Het Rot et al., 2010; DiazGranados et al., 2010; Ibrahim et al., 2011; Murrough et al., 2013; Ionescu et al., 2016) and possibly in patients with chronic PTSD (Feder et…”
BackgroundInfluentialOpioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542
Interpersonal Processes in Depression
Hames, J. L., Hagan, C. R., & Joiner, T. E. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185553 · Cited by 499
Morphine use after combat injury in Iraq and post-traumatic stress disorder
Holbrook, T. L., Galarneau, M. R., Dye, J. L., Quinn, K., & Dougherty, A. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903326 · Cited by 429 · cited 1×
“Recent clinical reports have highlighted the potential therapeutic impact of opioids in PTSD; morphine administered during early resuscitation and trauma care was associated with reduced risk of a subsequent PTSD diagnosis after serious injury (Holbrook et al., 2010).”
BackgroundPharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis
Hoskins, M., Pearce, J., Bethell, A., Dankova, L., Barbui, C., Tol, W. A., van Ommeren, M., de Jong, J., Seedat, S., Chen, H., et al. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.148551 · Cited by 418
Buprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346 · cited 1×
“Compelling clinical evidence has demonstrated the potential of low doses of buprenorphine to rapidly alleviate depressive symptoms in treatment-resistant depressed patients (Bodkin et al., 1995; Nyhuis et al., 2008; Ehrich et al., 2014; Karp et al., 2014).”
BackgroundYovell, Y., Bar, G., Mashiah, M., Baruch, Y., Briskman, I., Asherov, J., Lotan, A., Rigbi, A., & Panksepp, J. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040535 · Cited by 311
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
Browne, C. A., & Lucki, I. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00161 · Cited by 285 · cited 2×
“From our data and others, low doses of ketamine (1–10 mg/kg) can alter mouse behavior on tests related to antidepressant activity, such as the FST, NIH test, and reversed the behavioral deficits induced following chronic mild stress (Autry et al., 2011; Browne and Lucki, 2013).”
BackgroundSelf-citationNucleus Accumbens μ-Opioid Receptors Mediate Social Reward
Trezza, V., Damsteegt, R., Achterberg, E. J. M., & Vanderschuren, L. J. M. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5492-10.2011 · Cited by 263 · cited 2×
“Conversely, activation of MORs is necessary for social reward (Trezza et al., 2011; Hsu et al., 2013; Resendez et al., 2013) and reinforcement of the rewarding properties of drugs of abuse (Charbogne et al.”
BackgroundSocial Defeat Stress-Induced Behavioral Responses are Mediated by the Endogenous Kappa Opioid System
McLaughlin, J. P., Li, S., Valdez, J., Chavkin, T. A., & Chavkin, C. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300872 · Cited by 253
Response of the μ-opioid system to social rejection and acceptance
Hsu, D. T., Sanford, B. J., Meyers, K. K., Love, T. M., Hazlett, K. E., Wang, H., Ni, L., Walker, S. J., Mickey, B. J., Korycinski, S. T., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.96 · Cited by 225
Raphe GABAergic Neurons Mediate the Acquisition of Avoidance after Social Defeat
Challis, C., Boulden, J., Veerakumar, A., Espallergues, J., Vassoler, F. M., Pierce, R. C., Beck, S. G., & Berton, O. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2383-13.2013 · Cited by 197 · cited 1×
“Social approach behaviors of susceptible and control mice were tested following CSDS in a social interaction open-field arena (42 cm × 42 cm × 42 cm), in which a wire-mesh cage was placed at the end of the arena (Challis et al., 2013).”
MethodSelf-citationEvaluation of Opioid Modulation in Major Depressive Disorder
Ehrich, E., Turncliff, R., Du, Y., Leigh-Pemberton, R., Fernandez, E., Jones, R., & Fava, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.330 · Cited by 169 · cited 2×
“Furthermore, ALKS-5461, a combination of buprenorphine and the mu opioid receptor antagonist samidorphan, also induced positive effects within 1 week of treatment for treatment-resistant depression (Ehrich et al., 2014).”
BackgroundDonahue, R. J., Muschamp, J. W., Russo, S. J., Nestler, E. J., & Carlezon, W. A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.014 · Cited by 161 · cited 1×
“Reversal of social interaction deficits after CSDS in mice has been previously reported with ketamine (Donahue et al., 2014; Brachman et al., 2016), but both studies used higher doses (20–30 mg/kg) than used in this study (10 mg/kg).”
ResultPharmacotherapy of PTSD: premises, principles, and priorities.
Ravindran, L. N., & Stein, M. B. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.037 · Cited by 153
Ionescu, D. F., Swee, M. B., Pavone, K. J., Taylor, N., Akeju, O., Baer, L., Nyer, M., Cassano, P., Mischoulon, D., Alpert, J. E., et al. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10056 · Cited by 126
Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors
Falcon, E., Browne, C. A., Leon, R. M., Fleites, V. C., Sweeney, R., Kirby, L. G., & Lucki, I. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.38 · Cited by 118 · cited 19×
“Thus, given that buprenorphine mediates antidepressant actions via KORs and anxiolytic effects with MORs, we hypothesized that both Oprk1 and Oprm1 mRNA expression would be altered in brain regions relevant to social interaction.”
BackgroundResultSelf-citationAltered central μ-opioid receptor binding after psychological trauma
Liberzon, I., Taylor, S. F., Phan, K. L., Britton, J. C., Fig, L. M., Bueller, J. A., Koeppe, R. A., & Zubieta, J.-K. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.021 · Cited by 118
Resendez, S. L., Dome, M., Gormley, G., Franco, D., Nevárez, N., Hamid, A. A., & Aragona, B. J. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4123-12.2013 · Cited by 93
Opiate Treatment in Depression Refractory to Antidepressants and Electroconvulsive Therapy
Nyhuis, P. W., Gastpar, M., & Scherbaum, N. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818638a4 · Cited by 90 · cited 1×
“Compelling clinical evidence has demonstrated the potential of low doses of buprenorphine to rapidly alleviate depressive symptoms in treatment-resistant depressed patients (Bodkin et al., 1995; Nyhuis et al., 2008; Ehrich et al., 2014; Karp et al., 2014).”
BackgroundDeletion of the mu opioid receptor gene in mice reshapes the reward-aversion connectome
Mechling, A. E., Arefin, T., Lee, H.-L., Bienert, T., Reisert, M., Ben Hamida, S., Darcq, E., Ehrlich, A., Gaveriaux-Ruff, C., Parent, M. J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601640113 · Cited by 80 · cited 2×
“…needed to alleviate the symptoms of PTSD. Modulation of the endogenous opioid system presents a potential opportunity for developing novel therapeutics for PTSD. Endogenous κ- (KOR) and μ- (MOR) opioid receptors are critical regulators of mood (Lutz and Kieffer, 2013; Mechling et al., 2016).”
BackgroundHurd, Y. L., Herman, M. M., Hyde, T. M., Bigelow, L. B., Weinberger, D. R., & Kleinman, J. E. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000319 · Cited by 75 · cited 2×
“…signaling and KOR activation in depressed patients and the utilization of PET ligands to assay KOR availability as a transdiagnostic maker of dysphoria in patients diagnosed with depression, anhedonia, and PTSD (Hurd et al., 1997; Hurd, 2002; Anderson et al., 2013; Pietrzak et al., 2014).”
BackgroundResultBryant, R. A., Mastrodomenico, J., Hopwood, S., Kenny, L., Cahill, C., Kandris, E., & Taylor, K. (2013) · Psychological Medicine · doi:10.1017/s0033291713000068 · Cited by 63
Seal, K. H., Maguen, S., Bertenthal, D., Batki, S. L., Striebel, J., Stein, M. B., Madden, E., & Neylan, T. C. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m09893 · Cited by 44 · cited 1×
“Similarly, a small study noted that the mixed opioid analgesic buprenorphine alleviated PTSD symptomology in patients diagnosed with comorbid chronic pain and PTSD (Seal et al., 2016).”
BackgroundThe Anti-Suicidal Potential of Buprenorphine: A Case Report
Striebel, J. M., & Kalapatapu, R. K. (2014) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.47.2.g · Cited by 31
Cited by
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0503-4 · Cited by 174
The opioid system and the social brain: implications for depression and suicide
Lutz, P., Courtet, P., & Calati, R. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24269 · Cited by 53
“Animal studies investigating this combination of drugs have suggested that its antidepressive-like effects in mouse models of depression and social defeat (Browne et al. 2018) may implicate both MOR (Robinson et al.”
BackgroundKetamine’s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors
Zaytseva, A., Bouckova, E., Wiles, M. J., Wustrau, M. H., Schmidt, I. G., Mendez-Vazquez, H., Khatri, L., & Kim, S. (2023) · eLife · doi:10.7554/elife.86022 · Cited by 48
“Nonetheless, there are mixed reports on ketamine’s effects in naïve controls (Browne et al., 2018; Dong et al., 2017; Franceschelli et al., 2015; Ma et al., 2013; Zhang et al., 2018).”
BackgroundPérez de la Mora, M., Borroto-Escuela, D. O., Crespo-Ramírez, M., Rejón-Orantes, J. D. C., Palacios-Lagunas, D. A., Martínez-Mata, M. K., Sánchez-Luna, D., Tesoro-Cruz, E., & Fuxe, K. (2022) · Cells · doi:10.3390/cells11111826 · Cited by 21
Metadata
- Authors
- Browne, C. A., Falcon, E., Robinson, S. A., Berton, O., & Lucki, I.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08-31
- Volume
- 21
- Issue
- 2
- Pages
- 164-174
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2753036652
- Cited by
- 56
- References
- 33
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.